News & Events about Seres Therapeutics Inc.
Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading microbiome therapeutics company, today announced that on February 1, 2023, the Compensation and Talent Committee of Seres board of directors granted inducement equity grants covering an aggregate of 48,750 shares of its...
Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its...
Business Wire
3 months ago
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing...
Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform PR Newswire CAMBRIDGE, Mass., Oct. 17, 2022 Dr. Khrer has more than 25 years of RNA research and development experience, including pioneering novel...
Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics? Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics? PR Newswire NEW YORK, Sept. 23, 2022 NEW YORK...